Detalhe da pesquisa
1.
Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.
BMC Med
; 22(1): 9, 2024 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38191387
2.
Multiscale deep learning framework captures systemic immune features in lymph nodes predictive of triple negative breast cancer outcome in large-scale studies.
J Pathol
; 260(4): 376-389, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37230111
3.
Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial.
Int J Cancer
; 151(8): 1394-1404, 2022 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35583992
4.
Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.
Br J Cancer
; 126(10): 1401-1409, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35124703
5.
BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.
Breast Cancer Res
; 22(1): 79, 2020 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32711554
6.
IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.
Int J Cancer
; 146(8): 2348-2359, 2020 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31490549
7.
Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes.
Breast Cancer Res
; 21(1): 90, 2019 08 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31391067
8.
Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.
Breast Cancer Res Treat
; 175(1): 149-163, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30680659
9.
Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences.
Br J Cancer
; 119(7): 832-839, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30287915
10.
Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot.
BMC Cancer
; 18(1): 761, 2018 Jul 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-30041599
11.
Targeted MS Assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera.
J Proteome Res
; 15(4): 1230-42, 2016 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26958999
12.
PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Breast Cancer Res
; 16(1): R13, 2014 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-24467828
13.
Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment.
Breast Cancer Res
; 16(1): R6, 2014 Jan 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-24447434
14.
PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy.
Int J Cancer
; 135(5): 1257-63, 2014 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24501006
15.
MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.
J Exp Med
; 220(11)2023 11 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37642941
16.
Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.
EMBO Mol Med
; 15(12): e17737, 2023 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37902007
17.
External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer.
Eur J Cancer
; 195: 113401, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37925965
18.
Deep learning-based breast cancer grading and survival analysis on whole-slide histopathology images.
Sci Rep
; 12(1): 15102, 2022 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36068311
19.
FER regulates endosomal recycling and is a predictor for adjuvant taxane benefit in breast cancer.
Cell Rep
; 39(1): 110584, 2022 04 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35385742
20.
Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.
Clin Cancer Res
; 28(5): 960-971, 2022 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34965952